Mark Farrah Associates reports a slowdown in Medicare Advantage market growth with detailed enrollment and market share data for early 2025. Key tools aid insurers in competitive analysis post-Open Enrollment Period.
April 2025 market update reveals insurer stock declines amid UnitedHealth earnings miss, offset by pharma gains led by Eli Lilly's drug innovation and strong healthcare sector earnings projections.
Nexalin supports bipartisan Health Tech Investment Act to expand Medicare reimbursement for FDA-approved AI medical devices, aiding innovation in mental health treatment.
Medicare Advantage increases federal spending but offers lower out-of-pocket costs for seniors. SCAN CEO Sachin Jain highlights program flaws, risk adjustment abuses, and broker roles.
Explore effective strategies for Medicare beneficiaries to reduce out-of-pocket healthcare costs, optimize insurance plans, and navigate coverage challenges in 2025.
The Health Tech Investment Act proposes expanded Medicare reimbursement for FDA-approved AI medical devices, supported by Nexalin Technology to improve access and innovation in healthcare.
April 2025 update on U.S. pharmaceutical regulation highlights executive orders, budget changes, CMS policies, IRA litigation, and 340B program developments shaping drug pricing and access.
The Health Tech Investment Act aims to create a consistent Medicare payment system for FDA-approved AI medical devices, enhancing patient access and improving healthcare outcomes.
Dr. Mehmet Oz confirmed as CMS leader, emphasizing Medicare and Medicaid modernization, targeting fraud, and navigating potential Medicaid funding challenges amid federal budget pressures.
Holly Hill mental health hospital in North Carolina addresses CMS and NCDHHS compliance issues to maintain Medicare program eligibility. Follow-up inspection results pending.
